Fig. 3
Disease- and health-related quality of life and disease severity in UC patients (mITT). The mean change of the total Inflammatory Bowel Disease Questionnaire score is presented in a revealing a statistically significant change in month 3 and month 24 in comparison to BL. A statistically significant decrease in disease severity was observed in month 3 as well as in month 24 after onset of golimumab treatment as shown in b. Health-related quality of life measured by SF-12 (c [PCS-12], d [MCS-12]) was also improved in UC patients at both time points when compared to BL data. Analyses were done for the mITT analysis set and p values were generated using the paired t test (*) or Wilcoxon ranked sum test (*1). n: number of patients. BL: baseline. SD: standard deviation. IBDQ: inflammatory bowel disease questionnaire. PMS: partial Mayo score. SF-12: 12-item short form health survey. PCS-12: physical condition score of the SF-12. MCS-12: mental condition score of the SF-12